The Result of Some Biomarker of Free Radical-Peroxidation of Lipids and Antioxidant System of Experimental Acute Infarction Model Induced by Coronary Artery Occlusion in Rats
AbstractBackground: Recently years, Increasing coronary artery disease, diabetes, and cancer in the worldwide. Epidemiological studies indicate that ischemic heart disease will constitute the major disease-burden worldwide by the year 2020. Myocardial infarction is invariably followed by numerous pathophysiological and biochemical alterations including hyperlipidemia, thrombosis, lipid peroxidation and free radical damage etc., leading to qualitative and quantitative changes of myocardium. Determination of in blood serum and cardiac tissue homogenate levels of cardiac biomarker cardiac specific troponin I and estimation of lipid peroxidation products and some antioxidants enzymes of experimental acute infarction model induced by coronary artery occlusion in rats. Materials and methods: Adult male Wistar rats, weighting approximately 180 to 200±20 gram, used for the experiment. The were divided randomly into 2 groups (6-8 animals in each group). They were distributed as follow: first group (healthy, non treatment), second group (control, experimental acute infarction model induced by coronary artery occlusion in rats, non treatment). We did coronary occlusion induced myocardial ischemia by Kogan A.K., Ambaga M /1979/‘s method.The experiment is 1st, 3rd, 7th, 14th 21st days blood samples were collected and used to determine in blood serum and cardiac tissue homogenate levels of cardiac biomarker cardiac specific troponin I (CTn-I) and estimation of lipid peroxidation products (MDA, SA, LPO) and some antioxidants enzymes (SOD, GSH, GSH-px) were estimated using standard rat ELISA KIT by enzyme-linked immunesorbent assay. Result: Determination of cardiac troponin-I levels in blood serum of experimental acute infarction model induced by coronary artery occlusion in rats increased by 31.9-58.4% in the 1st, 3rd, 7th, 14th 21st days of the test compared to healthy groups. The cardiac biomarker cardiac specific troponin I is indicative for cardiomyocyte damage and is currently used in the diagnosis and prognosis of myocardial ischemia. Experimental acute infarction model induced by coronary artery occlusion in white rats, it is sufficiently shown that from day 1-21 MDA in plasma increased by 43.9 – 76.3%, plasma SA by 18.3-49.8% and LPO by 12.8-38.3%. This results in necrosis of cells and tissues, dissolving of membrane and stimulation of pathogenesis of disruption of membrane parts. It is also shown that substances such as endogen and antioxidant decreases in heart ischemia. Conclusion: Determination of increased level are lipid peroxidation products (MDA, SA, LPO, CTn-I), and decreased level are antioxidants (SOD, GSH, GSH-px) in blood serum of experimental acute infarction model induced by coronary artery occlusion in rats, it seems to induced of pathogenesis of coronary disease and infarction myocardium while the accumulation of lipid product cause to damage the cell membrane.
World Health organization. Global atlas on cardiovascular disease prevention and control 2011. 2011:7-15
WHO, Cardiovascular disease, Available at:http://www.who.int/mediacentre/factssheets/fs317/en/. [Accessed 17 May 2017].
R.Kleemann, S.Zadelaar, T.Kooistra. “Cytokines and atherosclerosis: a comprehensive review of studies in mice” Cardiovasc Res. pp. 360, 2008.
James N.B.M. de Andrade, Junnan Tang, Michael Taylor Hensley, Adam Vandergriff, Jhon Cores, Eric Henry, Tyler A. Allen, Thomas George Caranasos, Zegen Wang, Tianxia Zhang, Jinying Zhang, Ke Cheng. “Rapid And Efficient Production Of Coronary Artery Ligation And Myocardial Infarction In Mice Using Surgical Clips”. Doi:10.1371/Journal.Pone.014322, pp.1-2/11, November 24, 2015.
Hua Li, Yan-hua Xie, Qian Yang, Si-Wang, Bang-Le Zhang. “Protective effect of Paeonol and Danshu Combination on isoproterenol-induced myocardial ischemia in rats”. Plos one. volume number 7, issue 11, pp.1, 2012.
M.Ambaga, A.Tumen-Ulzii. “The full 9 stepped cycle of proton conductance and the time dependent disturbance of clockwise normal flow of electrons, protons during shortage of donators and acceptors”. International Journal of Current Research. Vol. 9, Issue, 08, pp.55902-55903. August.2017.
I.A.Katrukha. “Human Cardiac Troponin Complex. Structure and Functions”. Russian in Uspekhi Biologicheskoi Khimii. vol.53, pp. 1447. 2013.
P.Anversa, EH.Sonnenblick. “Ischemic cardiomyopathy: pathophysiological mechanisms”. Prog Cardiovasc Dis 33:49–70, 1990
AC.Hegstad, K.Ytrehus, R.Myklebust, L.Jorgensen. “Ultrastructural changes in myocardial myocytic mitochondria: crucial step in the development of oxygen radical induced damage in isolated rat hearts”. Basic Res Cardiol, pp.128–138, 1994.
J.Wu, JG.Hecker, N.Chiamvimonvat. “Antioxidant enzyme gene transfer for ischemic diseases”. Adv Drug Deliver Rev pp.61(4):351–363, 2009.
B.Sarantsetseg. “Antioxidant-lipid peroxidation free radical” system, their health science, pathology, significance of pharmacologic treatment”. Research dissertation for Doctor of Medical Science degree. Ulanbator, 1998.
M.Ambaga, A.K. Kogan, A.N. Kudrin “Pharmacotherapeutic action of cardioselective blockers of H1-adrenoreceptors (OF4647 and atenolol), Motley Astragalus, their combinations and Antioxidant-Dibunol in myocardial infarction caused by persistent and transient coronary occlusive ischemia (experimental study)”. Research dissertation for Doctor, Russia, 1984.
D.Ahn, L.Cheng, C.Moon, H.Spurgeon, EG.Lakatta, MI.Talan. “Induction of myocardial infarcts of a predictable size and location by branch pattern probability-assisted coronary ligation in C57BL/6 mice”. Am J Physiol Heart Circ Physiol. pp.286:1201–1207, 2004.
RD.Patten, MJ.Aronovitz, L.Deras-Mejia, NG.Pandian, GG.Hanak, JJ.Smith, et al. “Ventricular remodeling in a mouse model of myocardial infarction”. Am J Physiol. pp.274: 1812–1820, 1998.
LH.Michael, ML.Entman, CJ.Hartley, KA.Youker, J.Zhu, SR.Hall, et al. “Myocardial ischemia and reperfusion: a murine model”. Am J Physiol. pp.269: 2147–2154, 1995.
JA.Tallaj, V.Franco, BK.Rayburn, et al. “Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure”. J Heart Lung Transplant. pp.24: 2196-2201, 2005.
B.Sarantsetseg, M.Ambaga. “Lipid peroxidation-antioxidant system”. Ulanbator, pp.23, 1999.
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.